Bristol-myers Squibb Compnay

Eli Lilly and Company

Benjamin P Vokits

Scott A Shaw

Meriah Neissel Valente

Joanne M Smallheer

Nicholas Ronald Wurtz

Ellen K Kick

Andrew K Dilger

Sutjano Jusuf

Thomas Charles Britton

Charles G Clark

Carol Hui Hu

Kumar Balashanmuga Pabbisetty

Sean Patrick Hollinshead

Oz Scott Halpern

Andrew Quoc Viet

Adam Michael Fivush

Veronique Dehlinger

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

Spiroheptanyl hydantoins as ROCK inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same. 

Spiroheptanyl hydantoins as rock inhibitors

The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. 

Triazolopyridine inhibitors of myeloperoxidase

The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. 

Triazolopyridine inhibitors of myeloperoxidase and/or EPX

The present invention provides compounds of Formula (I): wherein A and Rare each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments. 

Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase

The present invention provides 3-indazoyl-4-pyridylisothiazoles or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods of using the same, as well as processes for preparing the same, and intermediates thereof.

3-indazolyl-4-pyridylisothiazoles

Growing community of inventors

New York, NY, United States of America

Benjamin P Vokits